This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NitroMed Readies for Drug Sales

NitroMed (NTMD) said Monday that its drug for treating congestive heart failure in African-Americans should be available within two to four weeks.

Michael Loberg, the president and CEO, didn't announce a price, but he said the drug BiDil will be "widely available" once the product launch begins. There will be "more than adequate quantities," he said.

Late Thursday after markets had closed, the Food and Drug Administration approved the drug, making it the first medication approved for a specific ethnic group. But the stock of the Lexington, Mass., company was halted Friday by the Nasdaq.

Loberg explained Monday, in a telephone conference call with analysts, that the Nasdaq halted trading because the company was negotiating with the FDA over the product expiration date for BiDil. The drug will have a 12-month expiration.

Since companies routinely manufacture products before getting FDA approval, the expiration-dating issue provoked questions from analysts who wanted to know if NitroMed might have unusable inventory. Loberg repeatedly said there wouldn't be any shortages.

Although BiDil is a patented product, it is a combination of two generic drugs -- hydralazine, for high blood pressure, and isosorbide dinitrate, for chest pains associated with heart disease. When asked by one analyst what the expiration dates were for the individual drugs, Loberg said he was not sure; but he added that he assumed the 12-month BiDil expiration was less than the expiration dates of the individual drugs.

Loberg reaffirmed his company's decision to market BiDil without a partner. NitroMed, which doesn't have any other products, has a 190-member sales force to promote the drug to physicians. "All launch elements are in place," Loberg said.

He said he believes that 85% of the African-American population of heart-failure age have some form of insurance coverage for the drug. The company is developing a patient assistance program for those who cannot afford the drug.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs